Literature DB >> 10618524

Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant Bacillus Catmette-Guérin (BCG).

N Ohara1, M Matsuoka, H Nomaguchi, M Naito, T Yamada.   

Abstract

Immunization of mice with recombinant Mycobacterium bovis Bacillus Calmette-Guérin (rBCG) which over-produces a putative protective antigen candidate, the A component of antigen 85 complex (Ag85A), reduced the multiplication of Mycobacterium leprae in the foot pads of mice. The inhibition by this rBCG (rBCG/85A) was more evident than that with parental BCG. Repeated rBCG/85A immunization significantly could reduce M. leplae multiplication in mice. This is first report of rBCG to control mycobacterial infection in animal model. Therefore, rBCG technique may be useful for the development of a more effective mycobacteria vaccine.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10618524     DOI： 10.1016/s0264-410x(99)00420-x

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

1.  Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection.

Authors:  E Martin; J A Triccas; A T Kamath; N Winter; W J Britton
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

2.  Co-infection of Mycobacterium tuberculosis and Mycobacterium leprae in human archaeological samples: a possible explanation for the historical decline of leprosy.

Authors:  Helen D Donoghue; Antónia Marcsik; Carney Matheson; Kim Vernon; Emilia Nuorala; Joseph E Molto; Charles L Greenblatt; Mark Spigelman
Journal:  Proc Biol Sci       Date:  2005-02-22       Impact factor: 5.349

Review 3.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

4.  A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.

Authors:  Audrey Tanghe; Pierre-Yves Adnet; Tatiana Gartner; Kris Huygen
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

Review 5.  Recombinant BCG as a vaccine vehicle to protect against tuberculosis.

Authors:  James A Triccas
Journal:  Bioeng Bugs       Date:  2009-11-02

6.  Pathogenesis and Host Immune Response in Leprosy.

Authors:  Hadida Yasmin; Praveen Mathews Varghese; Sanjib Bhakta; Uday Kishore
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.

Authors:  Vanitha S Raman; Joanne O'Donnell; H Remy Bailor; Wakako Goto; Ramanuj Lahiri; Thomas P Gillis; Steven G Reed; Malcolm S Duthie
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

Review 8.  Leprosy and tuberculosis co-infection: clinical and immunological report of two cases and review of the literature.

Authors:  Maria Ângela B Trindade; Denise Miyamoto; Gil Benard; Neusa Y Sakai-Valente; Dewton de M Vasconcelos; Bernard Naafs
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

9.  rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.

Authors:  Thomas P Gillis; Michael V Tullius; Marcus A Horwitz
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

10.  Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis.

Authors:  Neeraj Dhar; Vivek Rao; Anil K Tyagi
Journal:  Med Microbiol Immunol       Date:  2003-08-02       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.